IRIS
FERRERI, ANDRES JOSE MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 7.204
EU - Europa 6.273
NA - Nord America 3.984
SA - Sud America 2.018
AF - Africa 154
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 2
Totale 19.654
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 3.931
US - Stati Uniti d'America 3.767
SG - Singapore 2.704
CN - Cina 2.082
BR - Brasile 1.626
HK - Hong Kong 1.045
VN - Vietnam 733
SE - Svezia 631
IT - Italia 462
FR - Francia 367
DE - Germania 254
GB - Regno Unito 185
AR - Argentina 146
FI - Finlandia 123
IN - India 116
CA - Canada 95
EC - Ecuador 81
ID - Indonesia 78
MX - Messico 78
AT - Austria 69
BD - Bangladesh 69
JP - Giappone 59
IQ - Iraq 48
ZA - Sudafrica 48
NL - Olanda 43
CO - Colombia 41
PY - Paraguay 37
TR - Turchia 37
PL - Polonia 36
IE - Irlanda 35
SA - Arabia Saudita 31
ES - Italia 29
CL - Cile 28
EG - Egitto 27
VE - Venezuela 27
UA - Ucraina 26
PK - Pakistan 22
UZ - Uzbekistan 19
MA - Marocco 18
PE - Perù 18
PT - Portogallo 17
IR - Iran 16
KE - Kenya 16
AU - Australia 15
KR - Corea 14
TN - Tunisia 14
AE - Emirati Arabi Uniti 12
JO - Giordania 12
LT - Lituania 12
PH - Filippine 12
NP - Nepal 11
JM - Giamaica 8
MY - Malesia 8
UY - Uruguay 8
DZ - Algeria 7
KZ - Kazakistan 7
PS - Palestinian Territory 7
TH - Thailandia 7
BO - Bolivia 6
HN - Honduras 6
TW - Taiwan 6
AL - Albania 5
AZ - Azerbaigian 5
CH - Svizzera 5
CI - Costa d'Avorio 5
CZ - Repubblica Ceca 5
GG - Guernsey 5
IL - Israele 5
LB - Libano 5
NO - Norvegia 5
OM - Oman 5
SY - Repubblica araba siriana 5
TT - Trinidad e Tobago 5
YE - Yemen 5
BY - Bielorussia 4
ET - Etiopia 4
GT - Guatemala 4
HR - Croazia 4
KW - Kuwait 4
NG - Nigeria 4
PA - Panama 4
RS - Serbia 4
BB - Barbados 3
BG - Bulgaria 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
LV - Lettonia 3
MM - Myanmar 3
NI - Nicaragua 3
NZ - Nuova Zelanda 3
RO - Romania 3
SV - El Salvador 3
AM - Armenia 2
AO - Angola 2
BE - Belgio 2
BH - Bahrain 2
GA - Gabon 2
GE - Georgia 2
GR - Grecia 2
MN - Mongolia 2
Totale 19.635
Salva come PNG Salva come JPEG
Città #
Singapore 1.246
Hong Kong 1.042
Dallas 854
Moscow 843
Ashburn 505
San Jose 455
Shanghai 382
Hefei 345
Lauterbourg 298
Ho Chi Minh City 283
Lawrence 270
Princeton 270
Beijing 197
New York 151
São Paulo 136
Hanoi 133
Milan 120
Los Angeles 100
Nuremberg 84
Helsinki 83
Santa Clara 58
Munich 52
Belo Horizonte 47
Orem 47
Rio de Janeiro 45
Guangzhou 43
Rome 41
Tokyo 36
Chennai 35
Dublin 34
Montreal 33
Haiphong 32
Boardman 31
Da Nang 30
Turku 30
Biên Hòa 29
Vienna 29
London 28
Brasília 27
Johannesburg 27
Warsaw 27
Poplar 26
Guayaquil 25
Porto Alegre 25
Brooklyn 24
Council Bluffs 24
Houston 24
Quito 24
Hangzhou 23
Toronto 23
Asunción 22
Mexico City 22
Stockholm 22
Denver 21
Mumbai 19
Campinas 18
Frankfurt am Main 18
Jakarta 18
Leicester 18
Sorocaba 18
Tashkent 18
Boston 17
Chicago 17
Manchester 17
Osasco 17
Phoenix 17
Thái Bình 17
Baghdad 16
Goiânia 16
The Dalles 16
Tianjin 16
Amsterdam 15
Curitiba 15
Nairobi 15
Naples 15
Atlanta 14
Hải Dương 14
Santiago 14
Shenzhen 14
Buenos Aires 13
Columbus 13
Guarulhos 13
Salvador 13
San Francisco 13
Caxias do Sul 12
Paris 12
Riyadh 12
Santo André 12
Seattle 12
Washington 12
Daejeon 11
Dhaka 11
Florence 11
Ninh Bình 11
Ankara 10
Aracaju 10
Bắc Giang 10
Montes Claros 10
Taboão da Serra 10
Amman 9
Totale 9.512
Salva come PNG Salva come JPEG
Nome #
Definition, diagnosis, and management of intravascular large B-Cell lymphoma: Proposals and perspectives from an international consensus meeting 319
Radiomics-Based Machine Learning Model for Predicting Overall and Progression-Free Survival in Rare Cancer: A Case Study for Primary CNS Lymphoma Patients 159
ABS0671 IgG4-RELATED DISEASE IN OVERLAP WITH IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE: CLINICAL-PATHOLOGICAL CHARACTERISTICS AND THERAPEUTIC IMPLICATIONS OF AN ORPHAN DISEASE 146
A multicenter study of treatment of primary CNS lymphoma 143
BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome 141
THREE-HOUR INFUSION OF METHOTREXATE AT 3 g/m2 SIGNIFICANTLY REDUCES CNS RELAPSES AND IMPROVES SURVIVAL IN PATIENTS WITH LARGE B-CELL LYMPHOMAS AND INCREASED CNS RISK 134
Chronic lymphocytic leukaemia 130
A MULTICENTER TRIAL ASSESSING FEASIBILITY AND EFFICACY OF A COMBINATION OF HIGH-DOSE METHOTREXATE, CYTARABINE AND THIOTEPA IN PATIENTS WITH PRIMARY CNS LYMPHOMA: IMPACT ON OUTCOME OF CYTARABINE DOSE 129
A dose-dense short-term therapy for human immunodeficiency virus/acquired immunodeficiency syndrome patients with high-risk Burkitt lymphoma or high-grade B-cell lymphoma: safety and efficacy results of the “CARMEN” phase II trial 126
A PHASE II STUDY TO INVESTIGATE THE PREVALENCE OF INFECTIOUS AGENTS IN OCULAR ADNEXAE MARGINAL ZONE LYMPHOMA (OAMZL) AND THE EFFICACY OF ANTIBIOTIC THERAPY (IELSG#27 TRIAL) 126
Liquid biopsy of cerebrospinal fluid enabling the detection and therapeutic targeting of the BRAFV600E mutation in a patient with overlapping Erdheim-Chester/Rosai-Dorfman disease 123
Diagnosis and Treatment Using Autologous Stem-Cell Transplantation in Primary Central Nervous System Lymphoma: A Systematic Review 122
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL 121
A virtual tissue bank for primary central nervous system lymphomas in immunocompetent individuals 112
Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy 110
A First-in-human Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed/Refractory Hematologic Malignancies: Results From the European Study 110
A Six-Month Regimen of Oral Clarithromycin Is a Feasible and Active Therapy for Patients with Relapsed/Refractory Marginal Zone B-Cell Lymphoma of MALT-Type 107
SHORT-TERM DOSE-DENSE “CARMEN” THERAPY IS BETTER TOLERATED AND EVENLY EFFECTIVE THAN OTHER INTENSIFIED REGIMENS IN HIV- AND HIV+ PATIENTS WITH BURKITT LYMHOMA 106
Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi 102
A PHASE II TRIAL TO INVESTIGATE THE LINK WITH INFECTIOUS AGENTS IN OCULAR ADNEXAL MARGINAL ZONE LYMPHOMA, ESPECIALLY WITH CHLAMYDIA SPECIES, AND THE ANTINEOPLASTIC EFFECTS OF DOXYCYCLINE (IELSG#27) 100
Anti-CD20 monoclonal antibody (Rituximab) in gastric extranodal marginal zone (MALT) non-Hodgkin's lymphoma (NHL) patients: Clinical and biological results (Phase II study). 100
ABVD CAN BE SAFELY ADMINISTERED REGARDLESS OF ABSOLUTE NEUTROPHIL COUNT AND WITHOUT G-CSF SUPPORT IN HODGKIN'S LYMPHOMA PATIENTS 100
Quantitative muscle mass biomarkers are independent prognosis factors in primary central nervous system lymphoma: The role of L3-skeletal muscle index and temporal muscle thickness 100
Aggressive B-cell lymphoma with MYC/TP53 dual alterations displays distinct clinicopathobiological features and response to novel targeted agents 96
A phase 1/2 study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: The TIER trial 96
ORBIT IRRADIATION AS SALVAGE TREATMENT FOR PATIENTS WITH OCULAR ADNEXAL MALT LYMPHOMA (OAML) RELAPSED AFTER OR REFRACTORY TO CHLAMYDIA PSITTACI-ERADICATING ANTIBIOTIC THERAPY 94
Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: Final results of a phase 2 trial 94
Graft-versus-lymphoma effect inside the central nervous system in a patient with extranodal natural killer/T-cell lymphoma, nasal type 94
A narrative review of consolidation strategies for young and fit patients with newly-diagnosed primary central nervous system lymphoma 94
Activity of rituximab in extranodal marginal zone lymphomas (MALT-type). 92
Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells 91
A reappraisal of the diagnostic and therapeutic management of uncommon histologies of primary ocular adnexal lymphoma 90
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: Results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial 89
Adjuvant chemotherapy in ductal adenocarcinoma of pancreas: a comparison among three regimens 89
Bone Marrow Histopathology in the Diagnostic Evaluation of Splenic Marginal-zone and Splenic Diffuse Red Pulp Small B-cell Lymphoma: A Reliable Substitute for Spleen Histopathology? 87
FEASIBILITY AND EFFICACY OF CHLAMYDIA PSITTACI ERADICATION WITH PROLONGED DOXYCYCLINE THERAPY IN LOCALIZED OCULAR ADNEXAE MARGINAL ZONE LYMPHOMA (OAMZL): 7-YEAR RESULTS OF THE IELSG39 MULTICENTER TRIAL 86
The impact of histopathologic diagnosis on the proper management of testis neoplasms 86
Chlamydia infection and lymphoma: Multiple detection methods highlight an association beyond lymphomas of the ocular adnexa 86
MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study 86
Burden of Illness in Follicular Lymphoma with Multiple Lines of Treatment, Italian RWE Analysis 85
R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma 85
Clinical Experience in a Large Cohort of Patients with Vitreoretinal Lymphoma in a Single Center 85
A retrospective series of upfront therapy in primary brain lymphomas 85
A retrospective analysis of postradiation chemotherapy in 133 patients with glioblastoma multiforme 85
Chronic lymphocytic leukemia 84
Salvage Irradiation for Ocular Adnexal Mucosa Associated Lymphoid Tissue Lymphoma Refractory to Chlamydia psittaci Eradication 84
Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy 83
Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas 82
High Doses of Antimetabolites Followed by High-Dose Sequential Chemoimmunotherapy and Autologous Stem-Cell Transplantation in Patients With Systemic B-Cell Lymphoma and Secondary CNS Involvement: Final Results of a Multicenter Phase II Trial 82
Deep learning-based overall survival prediction model in patients with rare cancer: a case study for primary central nervous system lymphoma 81
Clinical Relevance of the Dose of Cytarabine in the Upfront Treatment of Primary CNS Lymphomas with Methotrexate-Cytarabine Combination 81
Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma 79
Prevention and management of secondary central nervous system lymphoma 79
Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation 79
Primary central nervous system lymphoma 79
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study 78
New hopes in relapsed refractory primary central nervous system lymphoma 78
MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas 78
Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study) 77
Central nervous system marginal zone B-cell lymphoma associated with chlamydophila psittaci infection 77
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial 76
Cyclin D3 immunoreactivity (IR) is an independent predictor of survival and drives the correct assessment of p27(KIP1) IR prognostic role in primary gastric lymphomas (PGL). 75
Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial 74
Gamma-delta t-cell lymphomas 71
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy 71
Cyclin D3 (CyD3) immunoreactivity (IR) is an independent predictor of survival and drives the correct assessment of p27 IR prognostic role in primary gastric lymphomas (PGL) 71
Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG) 68
Targeting the Blood–Brain Tumor Barrier with Tumor Necrosis Factor-α 67
AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma 67
Le infezioni erpetiche nel paziente immunocompromesso 67
Genomic complexity is associated with epigenetic regulator mutations and poor prognosis in diffuse large B-cell lymphoma 66
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53 66
Rituximab in patients with mucosal-associated lymphold tissue-type lymphoma of the ocular adnexa 66
Primary central nervous system lymphomas: Salvage treatment after failure to high-dose methotrexate 66
Characteristics and clinical outcomes of patients with ALK-positive anaplastic large cell lymphoma: Report from the prospective international T-cell lymphoma project 65
Clinical features, management and prognosis of multifocal primary bone lymphoma: A retrospective study of the international extranodal lymphoma study group (the IELSG 14 study) 65
Six-Month Doxycycline Is Safe and Effective As Upfront Monotherapy for Stage-I Malt Lymphoma of the Ocular Adnexae: Primary Endpoint Results of the IELSG39 Trial 65
KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: A FIL study 65
Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions 65
Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue 65
Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms 64
Prevalence of Borrelia Burgdorferi Infection in a Series of 98 Primary Cutaneous Lymphomas 64
Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL 64
Chlamydia infection and lymphomas: association beyond ocular adnexal lymphomas highlighted by multiple detection methods 64
Systemic vs. intrathecal central nervous system prophylaxis in primary adrenal/renal diffuse large b-cell LYMPHOMA: A multi-institution retrospective analysis and systematic review 64
Autologous hematopoietic cell transplantation versus whole-brain radiotherapy consolidation in primary central nervous system lymphoma: A systematic review and meta-analysis 63
Consolidation radiotherapy to bulky or semibulky lesions in the management of stage III-IV diffuse large B cell lymphomas 63
Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients 63
Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy 63
ALK-negative anaplastic large cell lymphoma: Features and outcomes of 235 patients from the International T-Cell Project 62
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial 62
Primary central nervous system lymphoma: Clinical characteristics and therapeutic management 62
Applying data warehousing to a phase III clinical trial from the Fondazione Italiana Linfomi ensures superior data quality and improved assessment of clinical outcomes 61
European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL) 61
Ocular Adnexal Lymphoma: Diffusion-weighted MR Imaging for Differential Diagnosis and Therapeutic Monitoring 61
Breaching the blood–brain tumor barrier for tumor therapy 61
Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: Results of a critical review of the literature 61
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial 60
Primary cardiac lymphoma in immunocompetent patients - Diagnostic and therapeutic management 60
MATILDE chemotherapy regimen for primary CNS lymphoma Results at a median follow-up of 12 years 60
Totale 8.726
Salva come PNG Salva come JPEG
Categoria #
all - tutte 124.234
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 124.234
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211 0 0 0 0 0 0 0 0 0 1 0 0
2021/2022232 0 0 2 71 9 6 16 91 4 5 1 27
2022/20231.341 631 271 56 6 9 135 42 86 53 10 17 25
2023/2024899 39 36 42 58 238 123 57 67 36 52 47 104
2024/20254.272 560 63 44 124 134 340 451 307 859 776 275 339
2025/202613.219 912 1.187 1.279 2.134 1.027 318 1.239 939 3.655 529 0 0
Totale 20.019